
    
      The infection with influenza is associated with higher morbidity and mortality in risk groups
      including immunocompromized patients. The virosomal influenza vaccines have been associated
      with improved immunogenicity in former trials. No direct comparison with older formulations
      has been conducted so far.
    
  